• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    2/14/24 4:31:06 PM ET
    $ADPT
    $AFIB
    $AZTR
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ADPT alert in real time by email

    Gainers

    • KalVista Pharma (NASDAQ:KALV) stock moved upwards by 11.0% to $15.99 during Wednesday's after-market session. The market value of their outstanding shares is at $552.5 million.
    • Anitra (AMEX:AZTR) stock increased by 9.25% to $0.25. The company's market cap stands at $3.0 million.
    • CytoMed Therapeutics (NASDAQ:GDTC) stock rose 7.5% to $2.58. The market value of their outstanding shares is at $29.7 million.
    • Vaccinex (NASDAQ:VCNX) stock rose 7.12% to $0.85. The market value of their outstanding shares is at $10.6 million.
    • Universe Pharmaceuticals (NASDAQ:UPC) shares moved upwards by 6.66% to $1.68. The company's market cap stands at $6.1 million.
    • Cidara Therapeutics (NASDAQ:CDTX) stock increased by 6.55% to $0.72. The market value of their outstanding shares is at $65.4 million.

    Losers

    • Adaptive Biotechnologies (NASDAQ:ADPT) stock declined by 8.6% to $3.6 during Wednesday's after-market session. The market value of their outstanding shares is at $521.1 million. The company's, Q4 earnings came out today.
    • Beyond Air (NASDAQ:XAIR) stock fell 8.11% to $1.7. The market value of their outstanding shares is at $61.2 million. As per the news, the Q3 earnings report came out 2 days ago.
    • Tenon Medical (NASDAQ:TNON) shares fell 6.93% to $1.21. The company's market cap stands at $2.9 million.
    • Ontrak (NASDAQ:OTRK) shares decreased by 6.76% to $0.17. The company's market cap stands at $4.7 million.
    • Panbela Therapeutics (NASDAQ:PBLA) stock decreased by 6.62% to $1.27. The company's market cap stands at $4.4 million.
    • Acutus Medical (NASDAQ:AFIB) stock declined by 6.57% to $0.18. The market value of their outstanding shares is at $5.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADPT
    $AFIB
    $AZTR
    $CDTX

    CompanyDatePrice TargetRatingAnalyst
    KalVista Pharmaceuticals Inc.
    $KALV
    1/9/2026$32.00 → $35.00Buy
    Needham
    KalVista Pharmaceuticals Inc.
    $KALV
    1/6/2026$28.00 → $32.00Buy
    Needham
    Adaptive Biotechnologies Corporation
    $ADPT
    12/2/2025$21.00Equal-Weight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Equal-Weight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Neutral
    Analyst
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Outperform → Sector Perform
    RBC Capital Mkts
    Cidara Therapeutics Inc.
    $CDTX
    10/16/2025$190.00Overweight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    10/10/2025$200.00Overweight
    Analyst
    More analyst ratings

    $ADPT
    $AFIB
    $AZTR
    $CDTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $35.00 from $32.00 previously

    1/9/26 7:49:25 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $28.00 previously

    1/6/26 7:58:35 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Adaptive Biotechnologies with a new price target

    Morgan Stanley resumed coverage of Adaptive Biotechnologies with a rating of Equal-Weight and set a new price target of $21.00

    12/2/25 8:23:20 AM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $AFIB
    $AZTR
    $CDTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Stein Jeffrey disposed of $339,040 worth of shares (5,190 units at $65.33), bought $339,040 worth of shares (4,262 units at $79.55), gifted 1,873 shares and received a gift of 937 shares, decreasing direct ownership by 44% to 5,763 units (SEC Form 4)

    4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

    1/7/26 8:12:25 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO and President Foster Steven M bought 19,455 shares, increasing direct ownership by 568% to 22,878 units (SEC Form 4)

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    11/18/25 8:42:50 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    Chief Innovation Officer Geist Wyatt D. bought 19,455 shares, increasing direct ownership by 14% to 157,569 units (SEC Form 4)

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    11/18/25 8:01:43 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    $ADPT
    $AFIB
    $AZTR
    $CDTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

    For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.  “Today’s authorization further und

    3/5/21 10:37:33 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $AFIB
    $AZTR
    $CDTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rubinstein Julie

    4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

    4/2/26 7:16:47 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Rubinstein Julie

    4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

    3/31/26 6:56:24 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Venrock Healthcare Capital Partners Iii, L.P.

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    3/27/26 5:50:10 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AFIB
    $AZTR
    $CDTX
    SEC Filings

    View All

    Beyond Air Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - Beyond Air, Inc. (0001641631) (Filer)

    4/1/26 4:30:07 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by CytoMed Therapeutics Limited

    6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)

    3/31/26 9:36:44 AM ET
    $GDTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by CytoMed Therapeutics Limited

    20-F - CytoMed Therapeutics Ltd (0001873093) (Filer)

    3/31/26 8:01:34 AM ET
    $GDTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AFIB
    $AZTR
    $CDTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted five newly-hired employees inducement options to purchase an aggregate of 66,375 shares of KalVista common stock on April 1, 2026 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the first day a closing price is reported following the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case

    4/2/26 4:01:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)

    GARDEN CITY, N.Y., April 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced it has been awarded a national group purchasing agreement for inhaled nitric oxide therapy with a leading U.S. group purchasing organization (GPO). Effective April 1, 2026, the agreement allows participating member hospitals and health systems to access the LungFit® PH system. This new agreement builds on Beyond Air's existing relationships with leading U.S. GPOs, including Vizient and Premier, Inc., further expanding access to a broad network of

    4/1/26 9:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference

    Interim data show sebetralstat enables early, effective treatment of hereditary angioedema (HAE) attacks in children with favorable safety and tolerability KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced new interim results from its KONFIDENT-KID clinical trial evaluating EKTERLY® (sebetralstat) for the on-demand treatment of hereditary angioedema (HAE) attacks in children ages 2-11 presented at the 2026 Global Angioedema Leadership Conference. KONFIDENT-KID is the largest pediatric trial ever conducted in HAE. It features a proprietary oral disintegrating tablet (ODT) formulation of sebetralstat in a population that currently relies on burdensome injectable treatments. The s

    3/30/26 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AFIB
    $AZTR
    $CDTX
    Leadership Updates

    Live Leadership Updates

    View All

    Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO

    GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi has resigned as Chief Executive Officer and stepped down from the Board of Directors, effective March 27, 2026, to pursue other opportunities. The Board of Directors has appointed Robert Goodman, the Company's current Chief Commercial Officer and Director, as Chief Executive Officer, effective today. For the past nine years, Mr. Lisi has led Beyond Air, guiding the development and launch of th

    3/26/26 4:05:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. "I am pleased to welcome Bilal and Linea to our leadership team as we advance the global launch of EKTERLY," said Ben Palleiko, Chief Executive Officer of KalVista. "Their respective expertise in operations and human resources will be instrumental as we deliver on our commitment to people living with HAE." "I am excited to join KalVista and collaborate with such a talented team," said Mr. Arif. "This is a pivotal time for EKTERLY, and I am focused on strengthening the operational framework to ensure pe

    10/6/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AFIB
    $AZTR
    $CDTX
    Financials

    Live finance-specific insights

    View All

    KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update

    $49.1 million global net product revenue of EKTERLY® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US from launch through end of February, reflecting continued rapid adoption of first and only oral on-demand treatment for hereditary angioedema (HAE) EKTERLY launched in Japan by partner Kaken Pharmaceutical Co., LTD Company to host conference call today at 8:30am ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today reported financial results for the eight months ended December 31, 2025, and provided a corporate update. As previously announced, the Company changed its fiscal year from ending April 30 of each year to ending Dece

    3/25/26 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review the Company's eight months fiscal year 2025 financial results and provide a corporate update. The live audio webcast will be accessible on the Investors section of the Company's website at www.ir.kalvista.com/event-calendar. An archived replay will be available on the site approximately two hours after completion of the event. About KalVista Pharmaceuticals, Inc. KalVista is a global pharmaceutical company dedicated to delivering life-changing therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discov

    3/18/26 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

    SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 was an outstanding year for Adaptive, marked by strong execution and meaningful progress across the business," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "We delivered 46% revenue growth and achieved profitability in our MRD business, while advancing our Immune Medici

    2/5/26 4:05:00 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $AFIB
    $AZTR
    $CDTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/9/24 5:37:15 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/4/24 4:15:14 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care